These Michigan Doctors Are Researching Two Cancers That Affect Women

Dr. Ira Winer and Dr. Joshua Dilworth are working to find treatments for ovarian and breast cancer.
238

What cancer patients want, besides a cure, is hope for a cure. Clinical trials — the process by which doctors and scientists test new and experimental treatments — search for new ways to combat disease, giving patients who have exhausted other treatments a crucial plan B. Here is a look at two Detroit-area doctors specializing in women’s health who are doing vital work in the field of hope.

Ovarian Cancer: Rethinking the Platinum Standard

Dr. Ira Winer, a gynecologic oncologist at the Karmanos Cancer Institute, is the principal investigator for multiple studies on cancers of the female reproductive system. For ovarian cancer, Winer is researching how to fight forms that are resistant to traditional chemotherapy.

Platinum-based chemo is standard for ovarian cancer, but up to 30 percent of ovarian cancer patients have resistance to this treatment. “Once [the cancer] has developed that resistance,” Winer says, “the patients don’t do as well.”

Winer is leading multiple clinical trials that give ovarian cancer patients with platinum chemo resistance another option. One study combines different immunotherapies that boost a patient’s immune system response.

Researchers make minute adjustments to treatments based on how the participant responds, combining an immunotherapy drug that already works with an experimental drug. The results have been so promising that the Food and Drug Administration granted a “fast track” designation to the treatment, expediting the approval process for mainstream use.

Breast Cancer: Tailor-Made Treatments

Dr. Joshua Dilworth, a radiation oncologist affiliated with Corewell Health William Beaumont University Hospital in Royal Oak, is the principal investigator on the TAILOR RT trial for breast cancer, the second most common cancer in women after skin cancer.

The Phase 3 trial (the stage where a new treatment is tested against standard treatments) is being conducted at medical institutions across the U.S. and Canada, with the hope of producing more effective treatments for women with ER- positive and HER2-negative breast cancer.

The trial has two goals. The first is to use tumor biology to guide treatment recommendations. In the past, tumor size and the number of cancer-affected lymph nodes determined whether or not radiation therapy to the chest area would be beneficial. But since all tumors are different, this trial tailors treatments based on a person’s individual genes.

“Cancer treatment is never one-size-fits-all,” Dilworth says. “You can have two patients, each with the same sized tumor and the same number of affected lymph nodes, … but each with very different risks of a cancer recurrence.”

The other goal of the study addresses how to avoid overtreating patients; reducing the intensity or duration of treatment (or even eliminating certain treatments entirely) to minimize side effects is known medically as “de-escalation.”

Radiation therapy targets and kills cancer cells, reducing the likelihood of a recurrence, but it has serious side effects. Yet radiation therapy might not make a significant difference for patients who have a biologically low-risk disease. If the patients in the trial who don’t receive radiation end up just as healthy as those who do, it doesn’t make sense for others in the same boat to continue with radiation therapy.

“We need to balance the risk of side effects with the benefit of the treatment,” Dilworth says. Decreasing the amount of treatment — and therefore those side effects — can improve a patient’s quality of life.

Doctors, hospitals, and medical schools are always recruiting subjects for clinical trials. Oncologists will often recommend a trial to eligible patients. Find a list of trials at clinicaltrials.gov. For the two institutions mentioned, visit their clinical trial search pages: beaumont.org and karmanos.org.


This story is from the October 2023 issue of Hour Detroit magazine. Read more in our digital edition.